Johnson & Johnson
Analysis Terminal
AI Sector Synthesis
AI analysis is currently unavailable as we process the latest market data streams. Please check back later for a updated summary.
Latest Market News
Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth
We just published a list of the 10 Worst Dow Stocks To Buy and Johnson & Johnson (NYSE:JNJ) ranked 6th on this list. Yahoo Finance reported on November 5 that the Dow Jones Industrial Average tumbled 3.4%, or more than 1,800 points, while the S&P 500 fell 4.4% and the Nasdaq Composite sank 5.5% into […]
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Johnson & Johnson (NYSE: JNJ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA), a marker used to monitor prostate cancer activity, including 47 percent (7 of 15 patients
Democrats Win Midterms: 5 Best Healthcare and Insurance Stocks To Buy
Healthcare stocks emerged as some of the clearest beneficiaries of the Democrats’ sweeping victory in the November 3 midterm elections, as investors reassessed the outlook for federal healthcare spending. With Democrats gaining control of both the House and Senate, expectations of potential changes to Medicaid funding and Affordable Care Act subsidies helped fuel a rally […]
3 Dividend Stocks Worth Researching This Weekend
Healthcare, net-lease real estate and oil each hide a dividend that has to survive a lawsuit, rising interest costs or a wild swing in crude. Which risk would you lose sleep over, and which payout earns your trust?
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Johnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16.2 Safety findings were consistent with the establ
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease (SjD), a chronic, systemic autoantibody-driven disease affecting approximately four million people worldwide.1 The results show that mouth dryness is the symptom improvement that matters most to patients,2 complementing previously reported Phase 2 study results on increased saliva production in patients who received nipocalimab.3 This was also the most
Is Intuitive Surgical's Next Big Thing Already Here?
For questions about this article or underlying research, email help@trefis.com.
What Could Stall AbbVie Stock's Run?
For questions about this article or underlying research, email help@trefis.com.
What Could Go Wrong At Boston Scientific From Here?
For questions about this article or underlying research, email help@trefis.com.
Should You Buy Globus Medical Stock For Its Cash?
For questions about this article or underlying research, email help@trefis.com.
Johnson & Johnson is a leading entity in the Pharmaceuticals sector, headquartered in US.
Professional Notice
Information is for educational purposes only. Market data is sourced via global nodes and is not financial advice.